Foghorn Therapeutics Inc.
Business
Foghorn Therapeutics Inc. is a clinical-stage precision oncology biotechnology company developing small-molecule therapies targeting the chromatin regulatory system to treat serious diseases, primarily cancers. The company's proprietary Gene Traffic Control platform enables identification and drug development against genetically-determined dependencies within chromatin regulatory complexes, with lead candidate FHD-909 (a selective SMARCA2 inhibitor) in Phase 1 development for SMARCA4-mutated non-small cell lung cancer and other solid tumors in collaboration with Eli Lilly. Foghorn's pipeline includes protein degraders and inhibitors targeting CBP, EP300, and ARID1B, with programs addressing over 20 tumor types and potential applications beyond oncology in immunology and inflammation.
Summary from 10-K filed 2026-03-11
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Collaboration revenue | 31 | 23 | 34 | 19 | 1 | |
| Research and development | 85 | 95 | 110 | 106 | 80 | |
| General and administrative | 28 | 28 | 32 | 31 | 22 | |
| Gain on lease modification | −2 | 0 | — | — | — | |
| Impairment of long-lived assets | 6 | 2 | 0 | — | — | |
| Total operating expenses | 117 | 125 | 142 | 136 | 102 | |
| Loss from operations | −86 | −103 | −108 | −117 | −101 | |
| Interest income | 9 | 12 | 11 | 6 | 59,000 | |
| Other income, net | 3 | 4 | 3 | 3 | 3 | |
| Total other income, net | 12 | 16 | 14 | 8 | −586,000 | |
| Net loss | −74 | −87 | −98 | −109 | −101 | |
| Net loss per share attributable to common stockholdersbasic (in dollars per share) | −1.18 | −1.58 | −2.34 | −2.62 | −2.73 | |
| Net loss per share attributable to common stockholdersdiluted (in dollars per share) | −1.18 | −1.58 | −2.34 | −2.62 | −2.73 | |
| Weighted average common shares outstandingbasic (in shares) | 63 | 55 | 42 | 42 | 37 | |
| Weighted average common shares outstandingdiluted (in shares) | 63 | 55 | 42 | 42 | 37 | |
| Unrealized gains (losses) on marketable securities | −111,000 | 961,000 | 3 | −4 | −3,000 | |
| Total other comprehensive gain (loss) | −111,000 | 961,000 | 3 | −4 | −3,000 | |
| Total comprehensive loss | −74 | −86 | −95 | −113 | −101 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 81 | 55 | 80 | 52 | 101 | |
| Marketable securities | 78 | 188 | 154 | 294 | 53 | |
| Restricted cash | 1 | 0 | — | — | — | |
| Prepaid expenses and other current assets | 3 | 6 | 6 | 6 | 5 | |
| Total current assets | 163 | 250 | 240 | 351 | 460 | |
| Property and equipment, net | 2 | 10 | 13 | 15 | 18 | |
| Restricted cash | 2 | 2 | 2 | 2 | 2 | |
| Other assets | 4,000 | 68,000 | 1 | 2 | 2 | |
| Operating lease right-of-use assets | 31 | 23 | 30 | 34 | 39 | |
| Total assets | 198 | 284 | 286 | 405 | 520 | |
| Accounts payable | 4 | 4 | 6 | 5 | 4 | |
| Accrued expenses and other current liabilities | 11 | 9 | 9 | 11 | 10 | |
| Operating lease liabilities | 923,000 | 9 | 9 | 6 | 7 | |
| Deferred revenue | 43 | 46 | 35 | 33 | 28 | |
| Total current liabilities | 60 | 67 | 58 | 55 | 49 | |
| Operating lease liabilities, net of current portion | 40 | 28 | 37 | 46 | 51 | |
| Deferred revenue, net of current portion | 206 | 234 | 268 | 304 | 323 | |
| Other liabilities | 556,000 | 0 | 0 | 29,000 | 143,000 | |
| Total liabilities | 307 | 330 | 363 | 405 | 423 | |
| Commitments and contingencies (Note 11) | — | — | — | — | — | |
| Preferred stock, $0.0001 par value; 25,000,000 shares authorized as of December 31, 2025 and 2024; no shares issued and outstanding as of December 31, 2025 and 2024 | 0 | 0 | 0 | 0 | 0 | |
| Common stock, $0.0001 par value; 175,000,000 shares authorized at December 31, 2025 and 2024; 56,657,329 shares issued and outstanding at December 31, 2025 and 55,594,131 shares issued and outstanding at December 31, 2024 | 6,000 | 6,000 | 4,000 | 4,000 | 4,000 | |
| Additional paid-in capital | 524 | 513 | 395 | 377 | 361 | |
| Accumulated other comprehensive gain | 24,000 | 135,000 | −826,000 | −4 | −10,000 | |
| Accumulated deficit | −633 | −558 | −472 | −373 | −264 | |
| Total stockholders deficit | −109 | −46 | −77 | 112,000 | 97 | |
| Total liabilities and stockholders deficit | 198 | 284 | 286 | 405 | 520 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation expense | 10 | 12 | 16 | 14 | — | |
| Depreciation and amortization expense | 3 | 3 | 4 | 3 | 3 | |
| Loss on disposal of property and equipment | 31,000 | 0 | 3,000 | 6,000 | 0 | |
| Noncash lease expense | 4 | 6 | — | — | — | |
| Accretion of discount on marketable securities | −2 | −5 | −3 | −1 | 179,000 | |
| Prepaid expenses and other current assets | 3 | 1 | 741,000 | −307,000 | −2 | |
| Accounts payable | 481,000 | −2 | 846,000 | 2 | 135,000 | |
| Accrued expenses and other liabilities | 2 | −564,000 | −2 | 1 | 3 | |
| Operating lease liabilities | −7 | −8 | −8 | — | — | |
| Deferred revenue | −31 | −23 | −34 | −14 | 336 | |
| Net cash used in operating activities | −86 | −100 | −118 | 194 | −50 | |
| Purchases of property and equipment | −50,000 | −906,000 | −1 | −1 | −3 | |
| Purchases of marketable securities | −131 | −261 | −74 | −409 | −100 | |
| Proceeds from maturities of marketable securities | 243 | 232 | 220 | 166 | 139 | |
| Net cash provided by (used in) investing activities | 112 | −30 | 144 | −244 | 36 | |
| Payments of public offering costs | 0 | −585,000 | 0 | — | — | |
| Proceeds from issuance of common stock upon exercise of stock options and employee stock purchase plan | 483,000 | 3 | 2 | 2 | 1 | |
| Net cash provided by financing activities | 1 | 105 | 2 | 2 | 22 | |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 27 | −25 | 28 | −49 | 8 | |
| Cash paid for taxes | 9,000 | 860,000 | 4 | — | — | |
| Purchases of property and equipment included in accounts payable and accrued expenses | 0 | 22,000 | 35,000 | 160,000 | 295,000 | |
| Asset acquired in finance lease | 1 | 0 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Foghorn Therapeutics Inc.'s CIK number?
Foghorn Therapeutics Inc.'s SEC CIK number is 0001822462 (1822462). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Foghorn Therapeutics Inc.'s SEC filings?
All of Foghorn Therapeutics Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Foghorn Therapeutics Inc. last report earnings?
Foghorn Therapeutics Inc. (FHTX) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001628280-26-031669). This is Foghorn Therapeutics Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Foghorn Therapeutics Inc.'s most recent earnings 8-K?
Foghorn Therapeutics Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001628280-26-031669. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Foghorn Therapeutics Inc.'s latest earnings 8-K →
Look up any company's CIK number →